Compare Equinor ASA (EQNR) vs Organon & Co. Common Stock (OGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Equinor ASA vs Organon & Co. Common Stock — how do they compare? Equinor ASA trades at $45 (market cap $105.42B), while Organon & Co. Common Stock trades at $13.58 (market cap $3.62B). The key difference: Equinor ASA is far larger — about 29.1× Organon & Co. Common Stock's market cap, and Equinor ASA pays the higher dividend (3.47%). Which is the better fit depends on your goals — on Pluang, investors hold Equinor ASA for 59 Days and Organon & Co. Common Stock for 0 Days on average.
| EQNR | OGN | |
|---|---|---|
Market Cap | $105.42B | $3.62B |
Volume | 4,977,357 | 2,892,999 |
Sector | Energy | Health |
52-Week High | $45.75 | $13.81 |
52-Week Low | $22.41 | $5.70 |
Typical Hold Time | 59 Days | 0 Days |
Enterprise Value | $114.11B | $11.04B |
Dividend Yield | 3.47% | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Equinor (EQNR) trades at $45.29, up 3.07% today, with a bullish technical signal from moving averages and a consensus analyst price target of $87.50 implying significant upside. Recent earnings show a mix of beats and one miss, while fundamentals reveal strong cash flow from operations of $20.0B in 2025 and attractive valuation ratios, including a P/E of 12.2 and EV/EBITDA of 2.47. The company is expanding its LNG portfolio and executing share buybacks, supporting positive sentiment.
The outlook for EQNR is positive, driven by undervaluation relative to analyst targets and strategic growth in LNG and carbon capture. Key risks include volatility in energy prices and execution of expansion plans. Earnings growth and dividend stability remain central to investor appeal, with the stock positioned for potential appreciation if operational targets are met.
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Equinor ASA
Equinor is a Norway-based integrated oil and gas company. It has been publicly listed since 2001, but the government retains a 67% stake. Operating primarily on the Norwegian Continental Shelf, the firm produced 2.1 million barrels of oil equivalent per day in 2021 (52% oil) and ended the year with 5.4 billion barrels of proven reserves (49% oil). Operations also include offshore wind, solar, oil refineries and natural gas processing, marketing, and trading.
Read more on EQNR →About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →
